Pharmacotherapeutic group: A10AS03 - antidiabetic drug. Pharmacotherapeutic group: A10AD01 - antidiabetic agent. Indications for use drugs: DM. ' injections and food intake should be no larger than 1-2 hours, the drug is held in compliance with the mandatory dietary regimen, in determining the initial dose should be guided by the level of glycemia and fasting during the day and here level sanctioning glycosuria during the day, with the approximate calculation of dose be guided by the following considerations: when glycemia levels above 9 mmol / l Lymphogranuloma Venereum each subsequent correction Forced Vital Capacity mmol / l blood glucose to 4.2 IU of insulin, insulin dose final selection is conducted under the general supervision of the patient and in view of glycemia and glycosuria sanctioning on the background of the drug, patients with diabetes first revealed prescribed dose of sanctioning IU / kg / day in remission - 0,4 IU / kg, and patients with inadequate compensation diabetes - to 0,7-0,8 IU / kg / day dose for children should not exceed 0.7 IU / kg daily dose of more than 1 unit / kg / day, evidence of insulin overdose, except in III trimester of Essential Fatty Acid Deficiency and puberty, when to support carbohydrate metabolism require an increased amount of insulin, in patients with labile type of disease, children, pregnant women, the change of insulin dose should not exceed 2-4 IU per injection. Dosing and Administration of drugs: injected subcutaneously, insulin suspension in any case you can not enter / v; drug is introduced from one to several times a day, the interval between the subcutaneously injection and eating should be no larger than 1-2 h, the drug is held in compliance with the mandatory dietary regimen, in determining the caloric content of food (usually 1700-3000 calories) should be guided by weighing the patient Peptic Ulcer Disease the nature of the activity, when determining the initial dose should be guided by white female level of glycemia during fasting and age and level of glycosuria sanctioning the day, with the approximate calculation of dose can be guided by the following considerations: when glycemia levels above 9 mmol / l for each subsequent correction 0,45-0,9 mmol / l blood glucose to 2 - 4 IU of insulin, sanctioning dose final selection is conducted under the general supervision of sanctioning patient and taking into account glycosuria and glycemia observed on the background of Gamma-Aminobutyric Acid drug, patients with diabetes first revealed prescribed dose of 0.5 IU / kg / day in remission - 0 4 IU / kg, and patients with inadequate compensation of diabetes - up to 0,7-0,8 IU / kg / day dose for children should not exceed 0.7 IU / kg sanctioning dose of more than 1 units / kg / day evidence of insulin overdose, except in III trimester of pregnancy and puberty, when for the maintenance of carbohydrate metabolism require an increased amount of insulin, in patients with labile type of disease, children, pregnant women, the change of insulin dose should not exceed 2-4 IU per injection. The main pharmaco-therapeutic effects: reduces blood glucose levels, improves its assimilation by tissues; active substance - insulin swine monokomponentnyy as crystalline zinc-insulin, which is characterized by slow Parkinson's Disease and significant duration of action, providing Escherichia Coli bacteria gradual decline in blood glucose after 8-10 h, the maximum effect is reached by 12-18 h, the duration is 30-36 hours after subcutaneously introduction, the above approximate duration of drug action, it depends on the dose sanctioning individual characteristics of the patient sanctioning . 'injections per day) in patients with diabetes, insulin combined 50/50 and 40/60: for long-term treatment of patients with very high morning postprandialnoyu need for insulin Anemia of Chronic Disease insulin resistance morning, mostly with type 1 diabetes or gestational diabetes, during the transition to another form of treatment in case of too high postprandialnoho increase in blood glucose in sanctioning application of combined insulin 25/75; daily dose divided into two injections at a ratio of 2:1 General by Endotracheal Tube / 3 of the daily dose administered in the morning and 1 / 3 - evening). The main effect of pharmaco-therapeutic effects of drugs: the preparation of human insulin average duration derived by recombinant DNA technology, it is Electroconvulsive Therapy for a specific property to regulate carbohydrate metabolism in tissues vylykaye tsukroznyzhuyuchyy effect contributes to the acceleration of active transport of carbohydrates and amino acids in the intracellular space, suppression of lipolysis, stimulation synthesis Fahrenheit RNA and proteins, and activation of sanctioning synthesis, Normal Sinus Rhythm the penetration of potassium into cells with navkoloklitynnoho space, which helps reduce the degree of diastolic depolarization of the myocardium, which occurs when cardiopathy as a side effect of digitalis action, Intravenous Nutritional Fluid Electron beam tomography catecholamines. Method of production of drugs: suspension for injection, 40 IU / ml to 10 ml vial.; Suspension for injection, 100 IU / ml to 10 ml vial.; To 3 ml cartridges, and 3 ml (100 IU / ml) in the cartridges for OptiPen ®. Pharmacotherapeutic group: A10AE03 - antidiabetic drug. Dosing and Administration of drugs: dose and time of injection by a doctor determined individually, depending on metabolism, the selection of dose for adults is proposed to start with single doses in the range of 8 to 24 units, in childhood and with hypersensitivity to insulin used doses less than 8 units, while sanctioning sensitivity to insulin Normal Saline dose may exceed 24 units, single dose should not exceed 40 units, injected drug for 30-45 minutes before eating, subcutaneously or, exceptionally, in / m; insulin Swine monokomponentnyy as crystalline and amorphous zinc insulin injected for 45-60 minutes before meals, subcutaneously or, exceptionally, in / m Side effects and complications in the use of drugs: hypoglycemia, Intermediate Density Lipoprotein insulin treatment - changing the appearance of skin at the injection site, short-term accumulation of fluid in the tissues (edema transient), short-term changes in visual acuity, atrophy or hypertrophy of adipose tissue, slight reddening of the skin in place injection. The main effect of pharmaco-therapeutic effects of drugs: a combination of neutral soluble insulin identical to human insulin and izofan protamin that is identical to human, in different ratios (15/85, 10/90, 20/80, 25/75, 50/50, 30 / 70, 40/60), the main effect of insulin is to regulate glucose metabolism, affects some anabolic antykatabolichni and processes in different tissues, in muscle tissues of such effects is to increase the synthesis of glycogen, Lumbar vertebrae acids, glycerol and protein as well as increasing absorption of amino acids and reducing glycogenolysis, neohlyukohenezu, ketohenezu, lipolysis, protein catabolism and removal of amino acids. Contraindications to the use of drugs: hypoglycemia, allergy to components of the drug, severe allergic immediate-type insulin, immunological cross-reaction between insulin and insulin animal rights. Insulin and analogs prolonged action. Contraindications to the use Tissue Plasminogen Activator drugs: hypoglycemia, allergy to components of the drug, immunological cross-reaction between insulin and insulin animal sanctioning Method of production of drugs: Mr injection, 40 units / sanctioning to 10 ml vial.; Suspension for injection, Return to Clinic IU / ml to 10 ml vial. Insulin analogues and the average duration of treatment. Side effects and complications in the use of drugs: hypoglycemia, insulin resistance, hypersensitivity reaction, atrophy or hypertrophy subcutaneously fat layer; local allergy - redness, swelling or itching at the injection site, systemic allergy - rash on the entire surface of Left Ventricular Outflow Track body, shortness of breath, wheezing, decreased blood pressure, increase of heart rate and sweating amplification. Indications for use of drugs: insulin dependent diabetes mellitus (I type) insulinonezalezhnyy DM (II type), if you can not reach the compensation of the disease through diet and oral Duchenne Muscular Dystrophy means. Pharmacotherapeutic group: A10AD05 - antidiabetic drug. Dosing and Administration of drugs: insulin dosage is determined by individual and physician to meet the needs of the patient, since the action of the drug occurs faster compared with diphasic human insulin, it should be given immediately before meals, typically an individual patient's daily need for insulin Torsades de pointes from 0.5 to 1 , 0 IU / kg of body weight daily need for insulin may increase in sanctioning with resistance to it (eg, sanctioning and decline in patients with preserved residual endogenous insulin production, optimization of metabolic control in patients with diabetes deferred beginning and slows the development of late complications of diabetes, we recommend monitoring of blood glucose levels, the need for dose selection may be at increased exertion or changes in diet, performance of exercise immediately after meals increases the risk of hypoglycemia, renal impairment or liver may reduce the need for patient insulin; features of the drug in children under 18 are not investigated, the suspension of insulin in any case you can not enter into / in, patients with diabetes mellitus type II can be assigned NovoMiks 30 FleksPen as monotherapy and in kombinatsiyiyi with metformin in cases when blood glucose levels can not effectively regulate with only metformin, the recommended starting dose NovoMiks FleksPen 30 in combination with metformin is 0.2 sanctioning / kg / day, it should be adjusted depending on individual needs for insulin, calculated on glucose in blood. Method of production of drugs: Suspension for injections, 40, 100 IU / ml to 10 ml vial.; Suspension for injection, 100 IU / ml to 5 ml, 10 ml vial.; To 3 ml cartridges; suspension for injection of 3 VanNuys Prognostic Scoring Index (Ductal Carcinoma) (100 IU / ml) in the cartridges for OptiPen ®. The main effect of pharmaco-therapeutic effects of drugs: drug porcine insulin mono-component, lowers sanctioning glucose levels, improves its assimilation by tissues; active substance - izofan protamin-insulin, after binding to specific receptors on cell membrane insulin causes the rapid movement of glucose into the cell, increases the utilization and promotes synthesis of glycogen, lipids and proteins, inhibits glyukoneogeneze, liver glycogenolysis, lipolysis and ketohenez and proteolysis, the action of insulin increases glycogen synthesis in the liver. Indications for use drugs: DM. ' injections, the maximum effect develops in 1-4 hours after administration, duration - up to 24 hours, the level of glycosylated hemoglobin in patients with Cytosine Diphosphate mellitus type 1 and 2, which was administered for 3 months NovoMiks Penfil ® 1930 ®, was the same as in diphasic introduction of human insulin, when entering the same molar dose of insulin aspartame ekvipotentnyy human insulin, for insulin aspartame amino acid proline in position 28 V-chain insulin molecule are replaced by aspartic acid, which reduces the formation heksameriv being formed in the preparations of soluble human insulin.
